What is SZLSF stock price today?

SZLSF (StageZero Life Sciences Ltd) stock is trading at $0.01 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is SZLSF stock going up or down today?

SZLSF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy SZLSF stock now?

The decision to buy SZLSF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is SZLSF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for SZLSF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is SZLSF stock overvalued or undervalued?

Use our DCF valuation calculator to determine if SZLSF is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is SZLSF's P/E ratio?

P/E ratio data for SZLSF will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is SZLSF's market cap?

SZLSF (StageZero Life Sciences Ltd) has a market capitalization of $0.00 billion, making it a small-cap stock.

What is SZLSF's price to book ratio?

SZLSF trades at a price-to-book (P/B) ratio of 5.60, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does SZLSF pay dividends?

SZLSF does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is SZLSF's dividend yield?

SZLSF does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is SZLSF stock a good long-term investment?

SZLSF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is SZLSF's revenue growth rate?

SZLSF has shown revenue growth of -0.3% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for SZLSF are available on our dashboard with complete income statement analysis.

What are the risks of investing in SZLSF?

Key risks for SZLSF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does SZLSF compare to its competitors?

Compare SZLSF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize SZLSF's performance and positioning.

What is SZLSF's stock price target for 2026?

Our AI model provides price targets for SZLSF based on fundamental analysis: Bull case $0.01 (+30%), Base case $0.01 (+15%), Bear case $0.00 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about SZLSF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for SZLSF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is SZLSF's next earnings report?

SZLSF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

SZLSF - StageZero Life Sciences Ltd

NYSE * Healthcare * Diagnostics & Research

$0.01

+$0.00 (+0.00%)

About StageZero Life Sciences Ltd

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer detection panel that tests blood for multiple discrete cancer. It also offers ColonSentry, a blood-based test to determine an individual's current risk for having colorectal cancer. The company is based in Richmond Hill, Canada.

SZLSF Key Statistics

Market Cap

$0.63M

P/B Ratio

5.60

EPS

$-0.12

Revenue Growth

-0.3%

Employees

How SZLSF Compares to Peers

SZLSF is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
SZLSF(This stock)	$630.02K	N/A	-0%	0.0%	-
UNHUnitedhealth Group	$285.06B	23.8	0%	0.0%	vs UNH
JNJJohnson &	$575.17B	21.8	0%	0.2%	vs JNJ
LLYEli Lilly	$809.09B	39.3	0%	0.3%	vs LLY
PFEPfizer Inc	$154.67B	20.0	-0%	0.1%	vs PFE
ABBVAbbvie Inc	$368.65B	87.6	0%	0.1%	vs ABBV

StageZero Life Sciences Ltd Company Information

Headquarters: 70 East Beaver Creek Road, Richmond Hill, ON, Canada, L4B 3B2, undefined
Website: www.stagezerolifesciences.com
Sector: Healthcare
Industry: Diagnostics & Research

About StageZero Life Sciences Ltd

SZLSF Key Statistics

How SZLSF Compares to Peers

StageZero Life Sciences Ltd Company Information

Upcoming Events for SZLSF